Claritas Rx Launches Consent Clearinghouse to Streamline Biopharma Patient Consent Management — Claritas Rx LLC

Event summary

Claritas Rx introduced Consent Clearinghouse™ on June 15, 2026, a solution for standardizing and centralizing patient consent across oncology, rare disease, and specialty biopharma.
The platform integrates consent data from multiple sources, including hubs, specialty pharmacies, and field reimbursement managers, into a unified dashboard.
Key features include real-time consent status visibility, audit-ready reporting for compliance, and seamless integration with existing CRM and specialty pharmacy platforms.
Claritas Rx also released a white paper and scheduled a webinar on August 19, 2026, to discuss consent management challenges in biopharma.

The big picture

Claritas Rx's Consent Clearinghouse addresses a critical operational and compliance challenge in the biopharma industry, where managing patient consent across multiple data sources has become increasingly complex. The solution aims to provide real-time visibility and control over consent data, reducing compliance risk and building trust infrastructure for responsible patient engagement. This launch comes at a time when the biopharma sector is navigating a patchwork of regulatory requirements and the emerging rules governing AI-driven engagement.

What we're watching

Regulatory Compliance: How the increasing complexity of regulatory environments, including HIPAA, GDPR, and state privacy laws, will impact the adoption of Consent Clearinghouse.
Market Adoption: The pace at which biopharma companies will integrate Consent Clearinghouse into their existing systems to manage patient consent more effectively.
Patient Trust: Whether the centralized consent management system will enhance patient trust and engagement, particularly in high-stakes areas like oncology and rare diseases.